Federal Register / Vol. 60, No. 90 / Wednesday, May 10, 1995 / Notices 24867

proposing analytical and theoretical research

on costs, quality, access, and efficiency of the

delivery of health services for the research

grant program administered by the Agency

for Health Care Policy and Research

(AHCPR).

Agenda: The open session of the meeting

on June 8 from 8:00 a.m. to 8:45 a.m. will be

devoted to a business meeting covering

administrative matters and reports. During

the closed sessions, the Subcommittee will

be reviewing and discussing grant

applications dealing with health services

research issues. In accordance with the

Federal Advisory Committee Act, section

10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C.

552b(c)(6), the Administrator, Agency for

Health Care Policy Research, has made a

formal determination that these latter

sessions will be closed because the

discussions are likely to reveal personal

information concerning individuals

associated with the applications. This

information is exempt from mandatory

disclosure.

Anyone wishing to obtain a roster of

members, minutes of the meeting, or other

relevant information should contact Patricia

G. Thompson, Ph.D., Scientific Review

Administrator, Scientific Review Branch,

Agency for Health Care Policy and Research,

Suite 602, Executive Office Center, 2101 East

Jefferson Street, Rockville, Maryland 20852,

Telephone (301) 594–1451.

Name: Health Care Technology Study

Section.

Date and Time: June 19–20, 1995, 8:00 a.m.

Place: Holiday Inn Crowne Plaza, 1750

Rockville Pike, Conference Room TBA,

Rockville, Maryland 20852.

Open June 19, 8:00 a.m. to 9:00 a.m.

Closed for remainder of meeting.

Purpose: The Study Section is charged

with conducting the initial review of health

services research grant applications

concerned with medical decisionmaking,

computers in health care delivery, and the

utilization and effects of health care

technologies and procedures.

Agenda: The open session on June 19 from

8:00 a.m. to 9:00 a.m. will be devoted to a

business meeting covering administrative

matters and reports. The closed session of the

meeting will be devoted to reviewing and

discussing grant applications dealing with

health services research issues. In accordance

with the Federal Advisory Committee Act,

Section 10(d) of 5 U.S.C., Appendix 2 and 5

U.S.C., 552b(c)(6), the Administrator, Agency

for Health Care for Policy and Research, has

made a formal determination that these latter

sessions will be closed because the

discussions are likely to reveal personal

information concerning individuals

associated with the applications. This

information is exempt from mandatory

disclosure.

Anyone wishing to obtain a roster of

members, minutes of the meeting, or other

relevant information should contact Karen

Rudzinski, Ph.D., Scientific Review

Administrator, Scientific Review Branch,

Agency for Health Care Policy and Research,

Suite 602, Executive Office Center, 2101 East

Jefferson Street, Rockville, Maryland 20852,

Telephone (301) 594–1437.

Name: Health Services Research

Dissemination Study Section.

Date and Time: June 29–30, 1995, 8:00 a.m.

Place: Chevy Chase Holiday Inn, 5520

Wisconsin Avenue, Palladian Room, Chevy

Chase, Maryland 20815.

Open June 29, 8:00 a.m. to 8:30 a.m.

Closed for remainder of meeting.

Purpose: The Study Section is charged

with the review of and making

recommendations on grant applications for

Federal support of conferences, workshops,

meetings, or projects related to dissemination

and utilization of research findings, and

AHCPR liaison with health care policy

makers, providers, and consumers.

Agenda: The open session of the meeting

on June 29 from 8:00 a.m. to 8:30 a.m. will

be devoted to general business matters.

During the closed portions of the meeting,

the Study Section will be reviewing and

discussing grant applications dealing with

health services research issues. In accordance

with the Federal Advisory Committee Act,

section 10(d) of 5 U.S.C., Appendix 2 and 5

U.S.C., 552b(c)(6), the Administrator, Agency

for Health Care Policy and Research, has

made a formal determination that these latter

sessions will be closed because the

discussions are likely to reveal personal

information concerning individuals

associated with the grant applications. This

information is exempt from mandatory

disclosure.

Anyone wishing to obtain a roster of

members, minutes of the meeting, or other

relevant information should contact Linda

Blankenbaker, Scientific Review

Administrator, Scientific Review Branch,

Agency for Health Care Policy and Research,

Suite 602, 2101 East Jefferson Street,

Rockville, Maryland 20852, Telephone (301)

594–1438.

Agenda items for all meetings are subject

to change as priorities dictate.

Dated: May 3, 1995.

Clifton R. Gaus,

Administrator.

[FR Doc. 95–11472 Filed 5–9–95; 8:45 am]

BILLING CODE 4160–90–M

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

HHS.

ACTION: Notice.

The inventions listed below are

owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of federally

funded research and development.

Foreign patent applications are filed on

selected inventions to extend market

coverage for U.S. companies and may

also be available for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated Licensing Specialist at

the Office of Technology Transfer,

National Institutes of Health, 6011

Executive Boulevard, Suite 325,

Rockville, Maryland 20852–3804

(telephone 301/496–7735; fax 301/402–

0220). A signed Confidential Disclosure

Agreement will be required to receive

copies of the patent applications.

2,5–Diamino-3,4–Disubstituted-1,6-FDiphenyhexane Isoteres Comprising

Benzamide, Sulfonamide and

Anthranilamide Subunits and Methods

Of Using Same

Randad, R.S., Erickson, J.W. (NCI)

Filed 20 Dec 94

Serial No. 08/359,612

Licensing Contact: Robert Benson (301/

496–7056 ext 267)

This invention concerns retroviral

protease inhibitors which are potential

drugs for the treatment of HIV infection.

The compounds of the invention

contain novel nonpeptidic and achiral

substituents, wherein achiral

benzamide, sulfonamide and

anthranilamide subunits are introduced

onto the 2,5-diamino-3,4-disubstituted1,6-diphenylhexane isostere core. The

compounds are more resistant to viral

and mammalian protease degradation.

The best compounds had a Ki

(inhibition constant) of less than 100

pM for HIV protease. CEM cells

chronically infected with HIV–1 were

used to test anti-retroviral activity. The

concentrations needed to inhibit 50% of

viral activity were on the order of 5 nM.

Therefore, these compounds compare

favorably in their anti-viral potency to

the best HIV protease inhibitors

currently in clinical trials. [portfolio:

Infectious Diseases—Therapeutics, antivirals, AIDS]

Conformationally Locked Nucleoside

Analogs

Marquez, V.E., Rodriguez, J.B., Nicklaus,

M.C., Barchi, J.J.

(NCI)

Filed 24 Sep 94

Serial No. 08/311,425 (CIP of 08/

126,796)

Licensing Contact: Carol Lavrich (301/

496–7735 ext 287)

Novel nucleoside analogues have

been developed that may facilitate

structure-function analysis of anti-HIV

compounds. Recently, there has been

intense interest in the design and use of

nucleoside analogues that can inhibit

the replication of viruses such as HIV–

1. The three-dimensional conformation

of such analogues has been implicated

in their ability to successfully inhibit

viral replication; however, in the past, it

has been difficult to conduct structure-
24868 Federal Register / Vol. 60, No. 90 / Wednesday, May 10, 1995 / Notices

function analyses because the sugar part

of the nucleoside is flexible and the

conformation often changes. These

newly developed nucleoside analoguess

make such studies more feasible

because they employ cyclopropanefused di-deoxynucleosides, which lock

the conformation of the sugar part of the

molecule in place. [portfolio: Internal

Medicine—Miscellaneous]

Mammalian Bilirubin UDPGlucoronosyltransferase Clones, and

Methods for Use Thereof

Owens, I., Ritter, J. (NICHD)

Filed 8 Sep 94

Serial No. 08/303,315 (CIP of 08/

209,688, FWC of 07/639,453)

Licensing Contact: Carol Lavrich (301/

496–7735 ext 287)

Liver transplantation is now the only

treatment for Crigler-Najjar Type I

syndrome. Other hyperbilirubinemic

syndromes are difficult and expensive

to diagnose. This cDNA clone encodes

a mammalian bilirubin UDPglucoronosyltransferase. Applications

include gene therapy for patients with

Crigler-Najjar Type I syndrome, a genebased fetal diagnostic probe for the

syndrome, and diagnostic tools for other

hyperbilirubinemic syndromes such as

Gilbert syndrome. [portfolio: Internal

Medicine—Miscellaneous]

Nucleotide and Deduced Amino Acid

Sequences of the Envelope 1 Gene Of 51

Isolates Of Hepatitis C Virus and the

Use Of Reagents Derived from These

Sequences in Diagnostic Methods and

Vaccines

Bukh, J., Miller, R.H., Purcell, R.H.

(NIAID)

Filed 15 Aug 94

Serial No. 08/290,665

Licensing Contact: Girish Barua (301/

496–7735 ext 263)

The invention is in the field of

hepatitis virology and relates to

complete nucleotide and deduced

amino acid sequences of the envelope 1

(E1) gene of hepatitis C virus (HCV)

isolates from around the world and the

grouping of these isolates into twelve

distinct HCV genotypes. More

specifically, this invention covers

oligonucleotides, peptides and

recombinant proteins derived from the

envelope 1 gene sequences of the 51

isolates of hepatitis C virus and to

diagnostic methods and vaccines which

employ these reagents. [portfolio:

Infectious Diseases—Vaccines]

Isolation of A New Murine Helicobacter

Bacteria, Tentatively Classified as A

Helicobacter Hepaticus

Ward, J.M., Fox, J.G., Collins, M.J.,

Gorelick, P.L., Benveniste,

R.E., Tully, J.G., Gonda, M.A. (NCI)

Filed 24 Jun 94

Serial No. 08/266,414

Licensing Contact: Girish Barua (301/

496–7735 ext 263)

An isolated bacterium of the genus

Helicobacter, characterized by the 16S

ribosomal RNA encoding nucleotide

sequence is described. An isolated

nucleic acid comprising the nucleotide

sequence is also defined. Such a nucleic

acid can be used for diagnosis of

infection with H. hepaticus. A nucleic

acid of the present invention in a vector

suitable for expression of the nucleic

acid is provided. The vector can be in

a host suitable for expressing the

nucleic acid. A purified antigen specific

for H. hepaticus and a method of

making an animal model for chronic

Helicobacter infection is also described.

[portfolio: Infectious Diseases—

Miscellaneous]

Cloning, Expression, and Diagnosis of

Human Cytochrome P450 2C19: The

Principal Determinant of SMephenytoin Metabolism

Goldstein, J.A., Romkes-Sparks, M.,

DeMorais, S. (NIEHS)

Filed 6 May 94

Serial No. 08/238,821 (CIP of 08/

201,118, CIP of 07/864,962)

Licensing Contact: Carol Lavrich (301/

496–7735 ext 287)

Two novel cytochrome P450 enzymes

have been isolated and characterized

that appear be the principal human

determinant of S-mephenytoin

metabolism. This invention has

particular application to the

development of more effective

anticonvulsant drugs. Mephenytoin is

used for the control of grand mal, focal,

Jacksonian, and psychomotor epileptic

seizures that are refractory to other

types of anti-convulsant drugs. In most

individuals, mephenytoin is

metabolized by 4/ -hydroxylation of Smephenytoin. This is accomplished by

a cytochrome P450 enzyme in liver

cells; however, some subpopulations of

individuals have defects in this P450

enzyme, resulting in reduced levels of

S-mephenytoin 4/ -hydroxylase activity

and severe side effects. The DNA

sequence that encodes enzymes from

the cytochrome P450 2C subfamily of

enzymes has been isolated and cloned.

Polymorphisms of these enzymes,

designated 2C18 and 2C19, appear to be

the principal reason that certain

individuals cannot effectively

metabolize S-mephenytoin and, thus,

have adverse side effects with this drug.

This invention provides purified

cytochrome P450 2C19 peptides and

purified cytochrome P450 2C18

polypeptides, as well as the CDNA

encoding these polypeptides. The

invention, among other things, also

provides methods for screening for a

drug that is metabolized by Smephenytoin 4/ -hydroxylase activity,

for determining the metabolites

activated by a xenobiotic or

carcinogenic compound, and for

diagnosing patients with a deficiency in

S-mephenytoin 4/ -hydroxylase activity.

[portfolio: Internal Medicine—

Miscellaneous]

Rotavirus Strain And Related

Composition

Glass, R.I., Gentsch, J.R., Das, B.K.,

Bhan, M.K. (CDC)

Filed 15 Apr 94

Serial No. 08/231,041

Licensing Contact: Girish Barua (301/

496–7735 ext 263)

Rotavirus is the leading cause of

severe diarrheal disease in infants in

both developed and developing

countries, and development of a vaccine

for this disease is therefore a global

priority. The availability of both cloned

rotavirus genes and protein sequences of

important rotavirus antigens should

permit yet additional approaches to

vaccine development.

This invention covers an isolated

rotavirus of strain G9P11 and an

isolated nucleic acid encoding the

rotavirus and a purified antigen specific

for rotavirus. An isolated nucleic acid

that selectively hybridizes under high

stringency conditions with the nucleic

acid encoding the virus is provided. A

purified antibody which selectively

binds the virus of strain G9P11 is

covered. The G9P11 rotavirus in a

pharmaceutical carrier for

administration in an immunization

protocol is disclosed. Also provided are

an isolated rotavirus of strain G9P11,

wherein the G9 gene and P11 gene are

substituted. [portfolio: Infectious

Diseases—Diagnostics, viral; Infectious

Diseases—Vaccines, viral]

Hepatitis C Virus Core Peptide for

Stimulation Of Cytotoxic T

Lymphocytes

Berzofsky, J.A., Feinstone, S.M., Shirai,

M. (NCI)

Filed 8 Apr 94

Serial No. 08/224,973

Licensing Contact: Girish Barua (301/

496–7735 ext 263)

The invention covers a series of

peptide fragments of hepatitis C virus

core protein and their use as activators

of cytotoxic T lymphocytes. The

peptides can be used as vaccines or

components of vaccines to prevent

hepatitis C. Besides the peptide
Federal Register / Vol. 60, No. 90 / Wednesday, May 10, 1995 / Notices 24869

fragments, pharmaceutical compositions

and methods of immunization and

diagnostics are also claimed. [portfolio:

Infectious Diseases—Therapeutics, antivirals]

Superactive Vasoactive Intestinal

Peptide Antagonist

Gozes, I., Brenneman, D.E., Fridkin, M.,

Moody, T.W. (NICHD)

Filed 7 Feb 94

Serial No. 08/194,591

Licensing Contact: Carol Lavrich (301/

496–7735 ext 287)

A potent antagonist of the vasoactive

intestinal polypeptide (VIP) has been

developed that may be useful in

inhibiting the growth of certain kinds of

lung cancers, among others. VIP is a

widely distributed peptide hormone and

neurotransmitter that mediates a variety

of physiologic responses including

gastrointestinal secretion; relaxation of

gastrointestinal, vascular, and

respiratory smooth muscle; pituitary

hormone secretion; and penile erection.

Receptors for VIP also have been

detected in cells derived from small cell

lung carcinoma and three other major

types of lung cancer, and VIP has been

shown to promote the growth of these

types of lung cancers. Traditionally,

lung cancer is treated with chemo- and/

or radiation therapy, but survival rates

for these types of therapies are quite

low. Researchers have now developed a

number of short polypeptide sequences

that are able to bind to VIP receptors in

various types of cells but do not display

biologic activity. Thus, these

polypeptides are potent inhibitors of

VIP activity and may be effective

chemotherapeutic agents in the

treatment of certain VIP-sensitive lung

cancers. These polypeptides, which are

designed to discriminate between the

various VIP receptors in the body, also

may be useful for delineating the

physiologic function of VIP in the CNS

and other tissues. [portfolio: Internal

Medicine—Miscellaneous]

IgE-Binding Epitopes of A Major HeatStable Crustacean Allergen Derived

From Shrimp

Metcalfe, D.D., Martin, B.M., Rao, P.V.S.

(NIAID)

Filed 10 Nov 93

Serial No. 08/149,809

Licensing Contact: Carol Lavrich (301/

496–7735 ext 287)

Epitopes of a major heat-stable shrimp

allergen, which may be valuable for

desensitizing individuals who are

allergic to shrimp and other crustacea,

have been developed. Crustacea are

among the foods most frequently

associated with immunoglobulin E

(IgE)-mediated type I hypersensitive

reactions in individuals with food

allergies. Previously, there has been no

method for effectively desensitizing

individuals to crustacea-related allergic

reactions. This problem has been

overcome by isolating the IgE allergenic

epitopes of the SA-I and SA-II heatstable shrimp antigens. These

epitopes—or their peptide derivatives—

could potentially be given to patients in

order to desensitize them to the

antigens. The use of antigenic epitopes

for desensitization is preferable to using

the entire antigen because it minimizes

the possibility of a severe adverse

reaction. Because this IgE-binding

antigen is highly conserved among

crustacea, potential application includes

diagnosis and treatment of a wide range

of crustacea-induced allergies with only

these two allergenic epitopes. [portfolio:

Internal Medicine—Miscellaneous]

Nitric Oxide-Releasing Compounds for

the Sensitization Of Hypoxic Cells in

Radiation Therapy

Mitchell, J.B., Krishna, M.C., Wink, D.,

Liebman, J.E., Russo, A. (NCI)

Filed 8 Oct 93

Serial No. 08/133,574

Licensing Contact: Carol Lavrich (301/

496–7735 ext 287)

A novel method has been developed

for sensitizing oxygen-poor, or hypoxic,

tumor cells, which will increase the

effectiveness of radiation treatment. It

has long been known that ionizing

radiation is more effective in killing

cancer cells if the cells are in an oxygenrich environment; however, the farther

tumor cells are away from the blood

supply, the more hypoxic they are and

the more resistant they are to radiation

therapy. Current methods for delivering

oxygen to hypoxic cells have limitations

because they are toxic to normal tissue,

require oxygen for their activity, or they

have too short a half-life. This

development overcomes such problems

by employing a nitrous oxide (NO)-

containing compound that

spontaneously releases NO under

physiologic conditions without

requiring oxygen. This compound—

which has a relatively long half-life and

is nontoxic to normals cells—has the

dual advantages of being able to

sensitize hypoxic tumor cells to ionizing

radiation while protecting normal cells

from the effects of radiation. [portfolio:

Internal Medicine—Therapeutics,

cardiology]

Transmission-Blocking Vaccine Against

Malaria

Kaslow, C.K., Isaacs, S., Moss, B.

(NIAID)

Filed 23 Aug 93

Serial No. 08/110,457 (CON of 07/

908,765, CON of 07/658,845)

Licensing Contact: Robert Benson (301/

496–7056 ext 267)

A transmission-blocking vaccine

developed against malaria contains a

recombinant virus, which encodes a

unique portion of the sexual-stage

surface antigen of Plasmodium

falciparum (referred to as Pfs25), or the

Pfs25 protein purified from infected

host cells. Mice inoculated with the

recombinant virus developed antibodies

capable of blocking transmission of the

virus. None of the mAbs known to block

transmission recognize the reduced

Pfs25 antigen. This vaccine, which

induces high, long-lasting titers at low

cost, can be useful for controlling

malaria. [portfolio: Infectious Diseases—

Vaccines, parasite]

Rat Thyrotropin Receptor Gene, and Its

Uses

Kohn, L.D., Akamizu, T., Ikuyama, S.,

Saji, M., Kosugi, S., Ban, T. (NIDDK)

Filed 29 Nov 93

Serial No. 08/064,058

Licensing Contact: Carol Lavrich (301/

496–7735 ext 287)

The rat thyrotropin receptor gene has

been cloned, which will make it

significantly easier to study this

important biologic receptor and to

develop therapies for thyroid gland

disorders. Thyrotropin, or thyroid

stimulating hormone (TSH), is a

pituitary hormone that regulates the

development and activity of the thyroid

gland. Abnormal binding of thyrotropin

to its specific thyroid cell receptor may

be the cause of variety of syndromes

such as hypothyroidism; however, the

in situ structure of the thyrotropin

receptor remains unclear because a

number of proteins appear to bind to it.

Pure sources of this receptor are

unavailable because of the

extraordinarily small numbers of

receptors in thyroid cells. Although

thyrotropin receptor genes previously

have been cloned for two species (dog

and human), a more desirable starting

point for elucidating the structure and

function of the thyrotropin receptor

would be to study it in a more utilizable

animal model, such as the rat. The gene

product of the cloned FRTL–5 rat

thyroid cell receptor can be used in

assays to look for ligands that bind to

the receptor. Truncated forms of the

protein also may be used for studying

the structure and function of various

domains of the receptor. Ultimately, this

invention is useful for developing

treatments for disorders arising from

dysfunctions of this receptor. [portfolio:

Internal Medicine—Miscellaneous]
24870 Federal Register / Vol. 60, No. 90 / Wednesday, May 10, 1995 / Notices

Nucleotide-Deduced Amino Acid

Sequence, Isolation, and Purification of

Heat Shock Chlamydial Proteins

Morrison, R.B., Caldwell, H.D. (NIAID)

Filed 25 Feb 92

Serial No. 07/841,323 (DIV of 07/

679,302, DIV of USPN 5,071,962)

Licensing Contact: Carol Lavrich (301/

496–7735 ext 287)

The chlamydial heat shock protein

(HSP60) is an immunodominant genus

common antigen which has been

implicated in immunopathologic

delayed type hypersensitivity reactions

during chlamydial infections. The HypB

gene which encodes the chlamydial

HSP60 has been cloned and

characterized. High levels of HSP60

expression have been obtained in

prokaryotic vectors and methods have

been developed for the purification of

the chlamydial HSP60 protein.

Availability of large quantities of

purified recombinant chlamydial HSP60

offers novel approaches to preventing,

treating, and diagnosing chlamydial

infections of humans. [portfolio:

Infectious Diseases—Diagnostics,

bacterial]

Methods and Compositions for

Diagnosing Cat Scratch Disease and

Bacillary Angiomatosis

Regnery, R.L., Anderson, B.E. (CDC)

Serial No. 07/822,539

Patent Issued 21 Mar 95

U.S. Patent No. 5,399,485

Licensing Contact: Carol Lavrich (301/

496–7735 ext 287)

A previously unidentified pathogenic

species of the rickettsia-like Bartonella,

named B. henselae, sp. nov., has been

identified and characterized. (Note: The

genus designation Bartonella is now

applied to and replaces the

Rochalimaea genus designation.) This

new organism causes two clinically

related diseases: Bacillary angiomatosis

and cat scratch disease. Currently,

diagnosis of Bartonella diseases is

limited to detection of the etiologic

agent associated with ‘‘trench fever’’,

referred to as B. quintata. Novel

diagnostic tests using

immunofluorescence assays or ELISAs

can detect the newly discovered

pathogen in sera from infected

individuals and distinguish it from B.

quintata, thus offering improved

differential diagnosis for disease

syndromes such as ‘‘trench fever’’,

bacillary angiomatosis, cat scratch

disease, and bacillary peliosis hepatitis.

[portfolio: Infectious Diseases—

Diagnostics, bacterial]

Effect of Cadmium on Human Ovarian

Cancer Cells With Cisplatin Resistance

Bo Lee, K., Parker, R.J., Reed, E. (NCI)

Filed 3 Mar 95

Serial No. 08/398,460

Licensing Contact: Raphe Kantor (301/

496–7735 ext 247)

The present invention describes

Cadmium (Cd) as a potential

anticarcinogenic compound useful in

treating ovarian cancer. The inventors

observed strong tumor suppressive

effects when applied to human ovarian

cancer cell lines in vitro. The effects of

Cd on cellular sensitivity, cellular drug

accumulation and efflux, and Cd-DNA

adduct formation and repair were

examined. Cadmium is shown to have a

subcellular profile that is similar,

though not identical, to cisplatin,

suggesting the possibility of future use

of CD as an anti-cancer agent. [portfolio:

Cancer—Therapeutics, conventional

chemotherapy, antimetabolites]

Trapping of Aflatoxins and

Phytoestrogens

Umrigar, P.P., Kuan, S.S. (FDA)

Filed 6 Jan 93

Serial No. 08/001,573

Licensing Contact: John Fahner-Vihtelic

(301/496–7735 ext 285)

A unique process has been invented

for removing aflatoxins and

phytoestrogens from food samples that

is a significant improvement over

currently available methods. Aflatoxins

are carcinogenic substances that are

found in foods such as grains and

peanuts and, thus, are a danger to public

health. Phytoestrogens—structurally

related to aflatoxins—are found in soy

products and also are of concern to

public health. Therefore, it is important

to be able to measure concentrations of

these compounds in foodstuffs. The

current method for determining

aflatoxin or phytoestrogen

concentrations in foods requires passing

a food sample through an affinity

column containing immobilized

antibodies specific for aflatoxins or a

solid phase extraction (SPE) column for

phytoestrogens. The bound aflatoxins or

phytoestrogens are eluted from the

affinity column and then measured

using high performance liquid

chromatography; however, such affinity

columns and SPE columns are

extremely expensive, have limited shelf

life, and cannot be reused. These

limitations have been overcome by

developing columns packed with new

derivatives of a copolymer of

cyclodextrin and epichlorohydrin.

These new copolymers, which have

proven particularly useful in trapping

aflatoxins and phyto-estrogens, are

extremely stable and are not damaged

when aflatoxins or phytoestrogens are

removed by a suitable solvent. Thus,

these materials are re-usable. [portfolio:

Devices/Instrumentation—

Miscellaneous]

Dated: May 1, 1995.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 95–11422 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–P

National Institute on Alcohol Abuse

and Alcoholism; Meetings

Pursuant to Public Law 92–463,

notice is hereby given of meetings of the

National Institute on Alcohol Abuse and

Alcoholism.

The National Advisory Council on

Alcohol Abuse and Alcoholism meeting

on June 1 will be open to the public, as

noted below, to discuss Institute

programs and other issues relating to

committee activities as indicated in the

notice. Attendance by the public will be

limited to space available. Individuals

who plan to attend and need special

assistance, such as sign language

interpretation or other reasonable

accommodations, should contract Ida

Nestorio at 301–443–4375.

The following meetings will be closed

to the public as indicated below in

accordance with the provisions set forth

in sections 552b(c)(4) and 552b(c)(6) of

Title 5, U.S.C. and section 10(d) of

Public Law 92–463, for the review,

discussion and evaluation of individual

research grant applications. These

applications and the discussions could

reveal confidential trade secrets or

commercial property such as patentable

material, and personal information

concerning individuals associated with

the applications, the disclosure of

which would constitute a clearly

unwarranted invasion of personal

privacy.

Summaries of the meetings and the

rosters of committee members may be

obtained from: Ms. Ida Nestorio, Office

of Scientific Affairs, National Institute

on Alcohol Abuse and Alcoholism,

Willco Building, Suite 409, 6000

Executive Blvd., Rockville, MD 20892–

7003, Telephone: 301–443–4375. Other

information pertaining to the meetings

can be obtained from the contact person

indicated.

Name of Committee: National Advisory

Council on Alcohol Abuse and Alcoholism.

Executive Secretary: James F. Vaughan,

6000 Executive Blvd., Suite 409, Bethesda,

MD 20892–7003, 301–443–4375.

Dates of Meeting: June 1, 1995.

Place of Meeting: Delegate Room D,

Building 45 (Natcher), NIH Campus, 9000

Rockville Pike, Bethesda, MD 20892.

Open: June 1, 10:30 a.m. to adjournment.